High-Density Lipoprotein Biomimetic Inorganic-Organic Composite Nanosystem for Atherosclerosis Therapy

被引:0
|
作者
Zhang, Yunpeng [1 ,2 ,3 ]
Liu, Danni [1 ,2 ,3 ]
Wang, Yaoqi [1 ,2 ,3 ]
Sun, Qi [1 ,2 ,3 ]
Mei, Dong [3 ,4 ]
Wang, Xiaoling [3 ,4 ]
Su, Yan [3 ,5 ]
Liu, Siyu [1 ,2 ,3 ]
Cui, Chunying [1 ,2 ,3 ]
Zhang, Shuang [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Sch Pharmaceut Sci, Beijing 100069, Peoples R China
[2] Minist Educ China, Beijing Area Major Lab Peptide & Small Mol Drugs, Beijing Lab Biomed Mat, Engn Res Ctr Endogenous Prophylact, Beijing 100069, Peoples R China
[3] Capital Med Univ, Lab Clin Med, Beijing 100069, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Pharm, Beijing 100045, Peoples R China
[5] Capital Med Univ, Beijing Childrens Hosp, Pediat Oncol Ctr, Natl Ctr Childrens Hlth,Med Oncol Dept, Beijing 100045, Peoples R China
基金
中国国家自然科学基金;
关键词
cerium-manganese hybridized nanoparticles; ApoA1; atherosclerosis; antioxidant; NANOPARTICLES; INFLAMMATION; NANOZYME; HDL;
D O I
10.3390/polym17050625
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Atherosclerosis (AS) is an important causative agent of cardiovascular diseases, and the occurrence and development of AS is accompanied by oxidative stress, so antioxidant therapy has become one of the strategies for the treatment of AS. This study aimed to design and construct an apolipoprotein ApoA1-modified inorganic-organic composite nanosystem for AS therapy, in which ApoA1 was modified onto carboxylated CeO2/Mn3O4 by covalent bonding, resulting in an inorganic-organic nanocomplex with a structure similar to that of high-density lipoprotein. The nanocomplex could effectively deliver the antioxidant nanoparticles to the AS plaque through the specific recognition between ApoA1 and the macrophage at the AS lesion site. For one thing, the nanocomplex could alleviate the oxidative stress environment of the AS site through the highly efficient antioxidant effect of CeO2/Mn3O4, which played a therapeutic role in the treatment of AS. For another, it could effectively eliminate the formed lipid plaques and maximally alleviate and treat AS by utilizing the cholesterol efflux effect of ApoA1.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] High-density lipoprotein infusion therapy: A review
    Brewer Jr, Bryan
    Schaefer, Ernst J.
    Foldyna, Borek
    Ghoshhajra, Brian B.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2024, 18 (03) : e374 - e383
  • [22] New targets of high-density lipoprotein therapy
    Nicholls, Stephen J.
    Nissen, Steven E.
    CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (04) : 421 - 426
  • [23] CHOLESTYRAMINE THERAPY AND HIGH-DENSITY LIPOPROTEIN METABOLISM
    THIRD, JLHC
    STEWART, JM
    PACKARD, CJ
    LAWRIE, TDV
    MORGAN, HG
    SHEPHERD, J
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1979, 9 (02) : 35 - 35
  • [25] HIGH-DENSITY LIPOPROTEIN SUBFRACTIONS IN NORMOLIPIDEMIC PATIENTS WITH CORONARY ATHEROSCLEROSIS
    BROOK, JG
    AVIRAM, M
    VIENER, A
    SHILANSKY, E
    MARKIEWICZ, W
    CIRCULATION, 1982, 66 (05) : 923 - 926
  • [26] Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
    Nicholls, Stephen J.
    Tuzcu, E. Murat
    Sipahi, Ilke
    Grasso, Adam W.
    Schoenhagen, Paul
    Hu, Tingfei
    Wolski, Kathy
    Crowe, Tim
    Desai, Milind Y.
    Hazen, Stanley L.
    Kapadia, Samir R.
    Nissen, Steven E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (05): : 499 - 508
  • [27] High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis
    Nofer, Jerzy-Roch
    JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (01) : 4 - 11
  • [28] Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
    Khera, Amit V.
    Cuchel, Marina
    de la Llera-Moya, Margarita
    Rodrigues, Amrith
    Burke, Megan F.
    Jafri, Kashif
    French, Benjamin C.
    Phillips, Julie A.
    Mucksavage, Megan L.
    Wilensky, Robert L.
    Mohler, Emile R.
    Rothblat, George H.
    Rader, Daniel J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (02): : 127 - 135
  • [29] CRADLE-TO-GRAVE ATHEROSCLEROSIS - HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
    GLUECK, CJ
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1982, 1 (01) : 41 - 48
  • [30] HIGH-DENSITY LIPOPROTEIN - A MAJOR RISK FACTOR FOR CORONARY ATHEROSCLEROSIS
    MILLER, NE
    BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1987, 1 (03): : 603 - 622